Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
Stock Score/grades
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
- Altman Z Score -2.65
- Piotroski Score 3.00
- Grade Buy
- Symbol (GNLX)
- Company Genelux Corporation
- Price $2.54
- Changes Percentage (3.21%)
- Change $0.08
- Day Low $2.40
- Day High $2.57
- Year High $16.60
Genelux Corporation, a clinical-stage biopharmaceutical company, focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Its lead product candidate is Olvi-Vec, a proprietary, modified strain of the vaccinia virus for the treatment of ovarian cancer and non-small-cell lung cancer. The company is also developing V2ACT Immunotherapy for the treatment of pancreatic cancer; and V-VET1 to treat hematologic and solid cancer. The company was incorporated in 2001 and is headquartered in Westlake Village, California.
- Last Earnings
- Ex-Dividend for 5/16 Dividend
- Dividend Payable
- Today N/A
- Next Earnings (Estimated) 04/07/2025
- Fiscal Year End N/A
- Average Stock Price Target $0.00
- High Stock Price Target $0.00
- Low Stock Price Target $0.00
- Potential Upside/Downside N/A
- Consensus Rating Sell
- Rating Score (0-4) N/A
- Research Coverage N/A
- EPS (Most Recent Fiscal Year) -$0.92
- Trailing P/E Ratio -2.48
- Forward P/E Ratio -2.48
- P/E Growth -2.48
- Net Income $-28,297,000
Income Statement
Quarterly
Annual
Latest News of GNLX
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
-
Genelux Corporation (GNLX) Stock Price, News, Quote & History - Yahoo Finance
Analysts predict two penny stocks to triple in value or more, labeling them as "Strong Buy". The current bull market is gaining momentum post-election, with expectations of looser regulations and pote...
By Yahoo! Finance | 1 week ago -
Is Genelux (NASDAQ:GNLX) In A Good Position To Invest In Growth?
Genelux (NASDAQ:GNLX) has a cash runway of 18 months with $34m cash and $22m cash burn. While analysts predict breakeven in 4 years, shareholders should consider potential dilution risks for raising m...
By Yahoo! Finance | 3 months ago -
Genelux Corporation (GNLX): A Strong Buy According to Hedge Funds
A list of the 10 Best New Penny Stocks includes Genelux Corporation (NASDAQ:GNLX), a leading immuno-oncology company with its main candidate, Olvi-Vec, showing promising results in clinical studies....
By Yahoo! Finance | 3 months ago
